Ginseng

證據等級: L5

預測適應症: 10 個

Ginseng: From Traditional Use to Drug-Induced Osteoporosis

One-Sentence Summary

Ginseng (DrugBank DB01404) is a traditional herbal preparation with no single defined original indication in the available regulatory data. The TxGNN model predicts it may be effective for Drug-Induced Osteoporosis, currently supported by 1 clinical trial and preclinical mechanistic rationale, though dedicated published literature for this specific indication is not yet available.

Quick Overview

Item	Content
Original Indication	Not on record — Ginseng is a traditional/adaptogenic herbal preparation with no single approved indication documented in this evidence pack
Predicted New Indication	Drug-Induced Osteoporosis
TxGNN Prediction Score	99.95%
Evidence Level	L3
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Ginseng. Based on known pharmacology, its active constituents (ginsenosides) have shown in preclinical/animal studies to promote osteoblast differentiation and inhibit osteoclast activity, which is the theoretical basis for a possible protective effect against bone loss — including drug-induced (e.g., corticosteroid-induced) osteoporosis.

This link is currently indirect: there is no confirmed human bone-metabolism mechanism specific to ginseng, and the supporting rationale is extrapolated from preclinical models rather than established clinical pharmacology. The one available human trial (NCT02763280) tested ginseng extract on bone metabolism in menopausal women — a related but distinct population from drug-induced osteoporosis — so mechanistic plausibility is present but not yet directly confirmed for this specific indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02763280	NA	Completed	90	12-week randomized, double-blind, placebo-controlled trial evaluating ginseng extract for improvement of bone metabolism in menopausal women; based on prior animal studies showing improved bone density and bone-related biomarkers. Relevance graded B — rigorous design but trial phase/endpoints not fully confirmed from available text.

Literature Evidence

Currently no related literature available for this indication.

South Africa Market Information

Ginseng currently has no SAHPRA registrations on record and is not marketed in South Africa (0 licenses). No product-level registration data is available for this evaluation.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: Warnings, contraindications, and drug interaction data for Ginseng are currently unavailable and are flagged as a blocking data gap for safety assessment (see Conclusion below).

Conclusion and Next Steps

Decision: Hold

Rationale: Ginseng is not currently registered or marketed in South Africa, and the safety data needed for even a preliminary risk assessment (warnings, contraindications) is entirely unavailable — this is a blocking gap. Combined with the absence of mechanism-of-action data and only a single, moderate-confidence (Grade B) trial in a related but not identical population, the evidence base is insufficient to move beyond a research question at this stage.

To proceed, the following is needed:

SAHPRA-approved Professional Information (PI) — warnings, contraindications, and drug interaction data
Verified mechanism of action data (e.g., from DrugBank or pharmacology literature)
Confirmation of NCT02763280’s actual endpoints (bone density/biomarker outcomes) to verify relevance to drug-induced osteoporosis specifically
Assessment of a regulatory pathway for market authorization in South Africa, given zero current SAHPRA registrations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.